List of Biosimilars Companies with Phase 1 Active Clinical Trial - 6

Founded in 2007, we are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing, and commercial capabilities as well as strong partnerships with organizations globally, we have developed a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. As we focus on delivering vaccines for a healthier world, we remain steadfast in our dedication to both scientific innovation and equitable access.

Dr. Reddy's Laboratories is a pharmaceutical company that specializes in pharmaceutical manufacturing and healthcare products.

Who we are Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207 About Biosimilars: Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion. Contact: Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg Germany phone +49 (0) 89 - 86 46 67 100 fax + 49 (0) 89 - 86 46 67 110 info@formycon.com

Kashiv BioSciences manufactures drug delivery systems and specialty drug products for the treatment of debilitating diseases.

NANOGEN BIOPHARMACEUTICAL is a leading company that is doing research and development of active Biopharmaceutical ingredients (APIs), and specific therapeutic injections in Asia Pacific region, based on advance in recombinant DNA and protein technologies. Nanogen offers a variety of gene-to-therapy biopharmaceuticals for the treatment of hepatitis B, hepatitis C, anemia due to chronic renal failure, oncology, etc. Our departments and facilities are integrated in the area of 15 000 square meters, located in Saigon Hi-tech Park Ho chi Minh City Vietnam. We research, develop, manufacture and market a wide range of therapeutic injection products under the strict compliance with current GMP and tight QC/QA procedures. Nanogen’s team consists of high-qualified scientists and graduates in diversity of biotechnology, pharmaceutical and healthcare. We have an international business network with the aim to produce high quality, affordable biotherapeutics.

Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs. Millions of patients with chronic conditions require biologic drugs, the vast majority of which must be injected. We have developed the RaniPill™ technology to replace subcutaneous or IV injections of biologics with an oral pill. The RaniPill™ capsule is designed to deliver an injection to the intestinal wall, where there are no sharp pain receptors, and has achieved bioavailability similar to subcutaneous injections. We believe oral versions of biologics will have the potential to transform medicine and improve outcomes for the millions of patients who currently rely on chronic self-injections.